
Product Data Sheet

Alexa Fluor[®] 700 anti-mouse Ly-6G

Catalog # / Size:	1238110 / 100 μg 1238105 / 25 μg
Clone:	1A8
Isotype:	Rat IgG2a, к
Immunogen:	Ly-6G transfected EL-4J cell line.
Reactivity:	Mouse
Preparation:	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration:	0.5



C57BL/6 bone marrow cells stained with 1A8 Alexa Fluor® 700

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

Application Notes: While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁵. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁵. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4¹⁶.

Additional reported applications (for the relevant formats) include: immunohistochemistry⁹ of frozen sections¹⁰ and paraffin-embedded sections¹¹, and depletion^{4, 12-14}. The LEAF^m purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 127620). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF^m purified antibody (Cat. No. 127632) with a lower endotoxin limit than standard LEAF^m purified antibodies (Endotoxin <0.01 EU/microg).

Application	1. Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399. (FC)
References:	2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
	3. Dietlin TA, <i>et al.</i> 2007. <i>J. Leukocyte Biol.</i> 81:1205. (FC)
	4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
	5. Tadagavadi RK, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:4904. <u>PubMed</u>
	6. Sumagin R, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:7057. <u>PubMed</u>
	7. Guiducci C, <i>et al.</i> 2010. <i>J. Exp Med.</i> 207:2931. <u>PubMed</u>
	8. Fujita M, <i>et al.</i> 2011. <i>Cancer Res.</i> 71:2664. <u>PubMed</u>
	9. Van Leeuwen, <i>et al.</i> 2008. <i>Arterioscler. Thromb. Vasc. Biol.</i> 28:84. (IHC)
	10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed

Antigen Fleming TJ, *et al.* 1993. *J. Immunol.* 151:2399. References: